Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Stock Rating Upgraded by StockNews.com

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Monday.

Other equities research analysts also recently issued reports about the stock. Cantor Fitzgerald restated an “overweight” rating and set a $21.00 price objective on shares of Actinium Pharmaceuticals in a research report on Monday, April 1st. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Actinium Pharmaceuticals in a research report on Monday. Finally, Maxim Group boosted their price target on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, March 19th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Actinium Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $25.72.

Actinium Pharmaceuticals Stock Up 4.2 %

NYSEAMERICAN:ATNM opened at $7.69 on Monday. Actinium Pharmaceuticals has a 1 year low of $4.00 and a 1 year high of $9.86. The stock has a market capitalization of $226.09 million, a price-to-earnings ratio of -4.20 and a beta of 0.01.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last issued its quarterly earnings results on Friday, March 29th. The biotechnology company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.21. The firm had revenue of $0.08 million during the quarter. As a group, equities research analysts anticipate that Actinium Pharmaceuticals will post -1.87 earnings per share for the current year.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in ATNM. Brandywine Global Investment Management LLC purchased a new stake in Actinium Pharmaceuticals in the 3rd quarter valued at $1,033,000. Sanders Morris Harris LLC purchased a new stake in shares of Actinium Pharmaceuticals in the first quarter valued at about $78,000. Finally, Creative Financial Designs Inc. ADV raised its holdings in shares of Actinium Pharmaceuticals by 19.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 3,175 shares during the last quarter. 27.50% of the stock is owned by institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.